Insulin-like Growth Factor 1 (IGF-1) is a hormone that plays a crucial role in muscle growth, body development, and overall physical performance. Human growth hormone (HGH) stimulates the release of IGF-1, which is essential for muscle growth and body development. IGF-1 is often compared to other growth factors due to its significant impact on cellular growth and repair.
INTRODUCTION TO INSULIN-LIKE GROWTH FACTOR (IGF-1)
Insulin-like growth factor (IGF-1) is a protein hormone produced primarily in the liver, playing a pivotal role in cell growth and development. This hormone is a key regulator of muscle growth, facilitating the proliferation and differentiation of cells. IGF-1 levels are closely linked to growth hormone levels, as growth hormone stimulates the liver to produce IGF-1. IGF-I is also involved in tissue repair, wound healing, and vascular health, highlighting its significance in regenerative processes. This relationship is crucial for maintaining optimal growth and development, particularly in skeletal muscle and bone tissue. IGF-1 binds with high affinity to receptors on muscle cells, promoting cell growth and division through autocrine signaling. Maintaining balanced IGF-1 and growth hormone levels is essential for proper bone development during childhood and sustaining muscle mass and strength in adulthood.
VARIANTS OF IGF-1: IGF-1 LR3 AND IGF DES 1,3
IGF-1 exists in two primary variants: IGF-1 LR3 and IGF DES 1,3. IGF-1 LR3 is a modified version of IGF-1, designed with an extended amino acid sequence that includes an additional 13 amino acids at the N-terminus and a substitution of arginine for glutamic acid at position 3. This modification results in a longer half-life of 20-30 hours, allowing IGF-1 LR3 to remain active in the body for an extended period, thereby enhancing its potency and effectiveness in promoting muscle growth and development. In contrast, IGF DES 1,3 is a truncated form of IGF-1, missing the first three amino acids at the N-terminus. This variant has a very short half-life of approximately 20-30 minutes, making it more suitable for localized, targeted muscle development. Despite its shorter duration of action, IGF DES 1,3 is highly effective at the injection site, rapidly binding to receptors on muscle cells and stimulating growth.
REVIEW FOR IGF-1 LR3 VS IGF DES 1,3
Although functionally related, IGF-1 LR3 and IGF DES 1,3 are two different compounds with different structures and degree of actions. This article will aim to explore the thin line that separates these closely related compounds in order to be able to identify them uniquely, for further research.
It will also attempt to fill readers in on what they must know about these two compounds, including their side effects, and further side-by-side analysis. Additional information will be posted on where you can go to buy them for any desired biological engineering or research purpose.
WHAT ARE INSULIN LIKE GROWTH FACTOR IGF-1 LR3 VS IGF DES 1,3 ?
IGF-1 LR3 stands for Insulin-like Growth Factor-1, Long Arginine 3.
The compound is a non-natural or artificial protein. It is a longer prototype of Insulin-like Growth Factor-1 ( IGF-1 ). Structurally, IGF-1 LR3 differs from its patent compound due to the presence of an Arginine in place of a glutamic acid at the third position of its amino acid sequence. Also, there is a presence of extra thirteen amino acids located in the N-terminus. This makes it loosely attracted to Insulin-like Growth Factor Binding Proteins ( IGFBPs ). IGF-1 LR3 and IGF DES 1,3 represent two groups of IGF-1 variants, each with distinct structural and functional properties.
The significance of this weak attraction towards IGFBPs is that the compound is able to exert increased pharmacological action in animal subjects, since IGFBPs decrease pharmacological activity of hormones which are strongly drawn to it. Additionally, IGF-1 LR3 has an extended half-life compared to the base form of IGF-1, allowing for a longer duration of activity in the body. This extended half-life enhances its effectiveness for bodybuilders and athletes by providing ample time to bind to receptors and exert hormonal effects.
On the other hand, IGF DES 1,3 stands for Insulin-like Growth Factor Desamino 1,3. It a natural variant of IGF-1 and extracted from human brain, porcine uterus and bovine colostrum. The compound lacks the first three amino acids located at the N-terminus which are present in the parent compound. The absence of these peptides provide it lesser affinity to IGFBPs, thereby boosting its efficacy because it will remain in the host body long enough to exert the desired pharmacological actions; cell proliferation. Both compounds are largely more potent than their parent compound; the IGF-1, in triggering hyperplasia or cellular mitosis upon injection into animal subject.
IGF-1 LR3 VS IGF DES 1,3 MOA (MECHANISM OF ACTION) AND LONGER HALF LIFE
To achieve even higher results than their parent IGF-1, IGF DES 1,3 and IGF-1 LR3 were independently used on animal subjects for trials. It was observed that they acted by binding to Insulin-like Growth Factor Binding Protein ( IGFBP ) in varying degree. IGF-1 LR3 stays in the host’s body for as long as 20-30 hours. Such long half-life means it is able to exert its pharmacological actions in the host’s body for the same length of time. IGF Des 1,3 had a shorter half-life and lasts in the host’s body for as little as 30 minutes, however that does not reduce its efficacy as a different approach in dosing it to laboratory rats made it more potent than its sister analogue compound – the IGF-1 LR3.
IGF-1 LR3 reduced the transport of glucose molecules into body cells, thereby triggering the use of triglycerides or fat cells in synthesizing energy for body use. Burning down of fat cells meant increase in the weight of real muscle.
IGF Des 1,3 also signals tissue growth, particularly during intense workouts, promoting hyperplasia and targeted muscle development.
The weight gain observed with IGF-1 therapy is primarily due to muscle growth rather than water retention. IGF Des 1, 3 on the other hand blinded to receptors of cells that are already deteriorated due to production of lactic acid during exercise. This means that they could be used and can quickly bind to these receptors of worn-out cells and trigger cellular division and hyperplasia during exercise.
It is important to note that higher doses of IGF-1, especially IGF-1 LR3, can increase the risk of hypoglycemia due to their effects on glucose transport.
EFFECTS OF IGF-1 LR3 AND IGF DES 1,3
The effects of IGF-1 LR3 and IGF DES 1,3 on the body differ significantly due to their structural variations and half-lives. IGF-1 LR3 is highly effective for overall muscle growth and development. It works by inhibiting the transport of glucose into cells, prompting the body to utilize fat stores for energy production, which can aid in fat loss and muscle gain. Studies suggest that IGF-1 levels may influence body fat reduction and metabolism, linking IGF-1 to changes in body fat and body mass index. Additionally, IGF-1 LR3 helps reduce inflammation and improve insulin sensitivity, contributing to better metabolic health.
On the other hand, IGF DES 1,3 is particularly effective for targeted muscle development. It stimulates hyperplasia, the increase in the number of muscle cells, making it ideal for muscle building and strength gain. Activating satellite cells with IGF-1 DES can result in more permanent gains in muscle mass, supporting lasting improvements especially during targeted injections and injury recovery. This variant is especially useful for repairing and regenerating muscle tissue in specific areas, enhancing localized muscle growth and recovery.
BENEFITS AND SIDE EFFECTS OF IGF-1 LR3 AND IGF DES 1,3
IGF-1 LR3 and IGF DES 1,3 are two powerful forms of insulin like growth factor that have gained attention for their roles in muscle growth, cell growth, and enhancing overall physical performance. Each variant offers unique advantages based on its half life and mechanism of action, making them suitable for different research and performance goals.
IGF-1 LR3, with its longer half life of approximately 20-30 hours, is especially valued for promoting sustained skeletal muscle growth and increasing muscle mass. Its extended duration allows for ongoing stimulation of muscle cells, supporting muscle cell proliferation, differentiation, and protein synthesis over a longer period. This makes IGF-1 LR3 a popular choice for those seeking significant increases in muscle growth and improved insulin sensitivity. Additionally, by promoting cell growth and enhancing tissue growth, IGF-1 LR3 can contribute to better recovery and adaptation following resistance training or intense workouts.
In contrast, IGF DES 1,3 is characterized by a very short half life of about 20-30 minutes, making it ideal for targeted muscle development and localized muscle growth. Its high affinity for IGF binding proteins allows it to act quickly at the injection site, stimulating hyperplasia and muscle cell proliferation in specific muscle groups. This makes IGF DES 1,3 particularly effective for post workout recovery, muscle repair, and promoting rapid growth in muscle tissue that has been subjected to intense physical performance.
Despite their benefits, both IGF-1 LR3 and IGF DES 1,3 come with potential side effects, especially when used in high doses or over extended periods. Common concerns include disruptions in blood sugar control, changes in insulin sensitivity, and the risk of hypoglycemia. High doses of IGF-1 LR3 may accelerate fat loss, while IGF DES 1,3 can sometimes lead to weight gain due to its potent effects on muscle and tissue growth. There are also broader metabolic considerations, such as the impact on metabolic syndrome, vascular aging, and the need to monitor protein intake to support muscle building and recovery.
It is important to note that both IGF-1 LR3 and IGF DES 1,3 are prohibited by the World Anti-Doping Agency, and their use can have serious consequences for competitive athletes. Long-term use may also affect growth hormone levels, insulin like growth, and overall metabolic health. As with any growth factor or hormone-related compound, there is a risk of adverse side effects, and responsible use under medical supervision is essential.
In summary, while IGF-1 LR3 and IGF DES 1,3 offer significant benefits for muscle growth, muscle mass, and physical performance, they should be used with caution. Understanding their differences in half lives, mechanisms, and potential side effects is crucial for anyone considering their use. Always consult with a healthcare professional before starting any regimen involving these compounds, especially if you have underlying health conditions or are taking other medications.
RESULTS FOR IGF DES 1,3 VS IGF-1 LR3
Both analogue compounds of IGF-1 acted as endocrine growth factors that had improved anabolic effects on the animal host’s muscular tissue, even though in varying degrees as IGF DES 1,3 was more potent than IGF-1 LR3 in achieving the same result.
Variations in IGF-1 levels can influence metabolic syndrome and factors like muscle strength, healing, and overall metabolic health, suggesting a complex interplay between these biological mechanisms.
IGF DES 1,3 was injected into a specific muscle group of the animal subject several times in a day before subjecting the rats into physical activities. These injections were often administered pre workout, approximately 15–30 minutes before activity, to maximize muscle pump and growth. Specific muscles of the rats were dosed with a measured vial of the compound. In less than two weeks, massive hyperplasia had occurred in the injected muscles as the cells in the tissues of those muscle had repeatedly proliferated. IGF DES 1,3 activates satellite cells, which are essential for muscle repair, hypertrophy, and the generation of new muscle fibers.
While IGF-1 Des 1,3 was administered in localized body parts for development of only those body parts, IGF-1 LR3 on the other hand was administered into a part of an animal subject for an overall body effect or development. Also, that IGF-1 LR3 lasts for more than 20 hours in the host’s body meant that it had a longer half-life compared to IGF Des 1,3’s thirty minutes half-life. These two reasons explain why IGF Des 1,3 vials had to be injected into animal subjects repeatedly in order to have a more significant results of hyperplasia.
Certain side effects were however recorded from use of these compounds on laboratory rats. Cases of dangerously low blood sugar content were specifically observed after serial administrations of IGF Des 1,3 in animal subjects. Both compounds also enhanced proliferation of cancerous cells in rats diagnosed of having cancerous tumours. IGF Des 1,3 in particular caused reversed testicular atrophy in male Rats that have withered testicles.
RESEARCH AND CLINICAL APPLICATIONS
Research has demonstrated that IGF-1 delivery strategies can significantly enhance tendon healing and improve muscle recovery following strain injuries. IGF-1 has also been linked to the regulation of atherosclerosis and vascular aging, with studies showing its role in modulating glutathione peroxidase expression and activity in vascular endothelial cells. Furthermore, IGF-1 is crucial for skeletal muscle growth, primarily through the IGF1-Akt/PKB signaling pathway, which promotes muscle cell proliferation and differentiation. Clinically, IGF-1 has been used to treat growth hormone deficiency, improving muscle strength and mobility, particularly in older women. However, the misuse of IGF-1 in sports remains a significant concern, necessitating the development of effective detection methods to prevent its abuse and ensure fair competition.
WHERE TO BUY IGF DES 1,3 and IGF-1 LR3
IGF-1 LR3 and IGF DES 1,3 are available at Loti Labs. IGF-1 LR3 and IGF DES 1,3 are commonly sold in 1mg vials and should be stored UN-reconstituted at a temperature of -20 degrees C.
References
- Philippou, A., Maridaki, M., Halapas, A., & Koutsilieris, M. (2014). The role of insulin-like growth factor 1 (IGF-1) in skeletal muscle growth and regeneration. Journal of Muscle Research and Cell Motility, 35(1), 1-10. https://doi.org/10.1007/s10974-013-9371-8
- Le Roith, D., Bondy, C., Yakar, S., Liu, J.-L., & Butler, A. A. (2001). The somatomedin hypothesis: 2001. Endocrine Reviews, 22(1), 53-74. https://doi.org/10.1210/edrv.22.1.0428
- Philippou, A., Halapas, A., Maridaki, M., & Koutsilieris, M. (2007). IGF-1 and exercise: A review of the current evidence of the effects of exercise on IGF-1 levels and actions. Hormones, 6(2), 87-95. https://doi.org/10.14310/horm.2002.1080
- Clemmons, D. R. (2004). Role of IGF-binding proteins in regulating IGF responses to changes in metabolism. Journal of Molecular Endocrinology, 32(1), 13-24. https://doi.org/10.1677/jme.1.01578
- Musaro, A. (2013). The role of IGF-1 in skeletal muscle hypertrophy and repair. Biochemical Society Transactions, 41(6), 1451-1456. https://doi.org/10.1042/BST20130135
- Le Roith, D. (2003). Insulin-like growth factors. The New England Journal of Medicine, 336(9), 633-640. https://doi.org/10.1056/NEJM199702273360906
- Philippou, A., Maridaki, M., & Koutsilieris, M. (2010). IGF-1 signaling and muscle regeneration: The role of IGF-1 variants. Cell Communication and Signaling, 8, 15. https://doi.org/10.1186/1478-811X-8-15
- World Anti-Doping Agency. (2024). Prohibited List. Retrieved from https://www.wada-ama.org/en/prohibited-list
- Lu, H., Huang, D., Saederup, N., Charo, I. F., Ransohoff, R. M., & Zhou, L. (2011). Macrophages recruited via CCR2 produce insulin-like growth factor-1 to repair acute skeletal muscle injury. FASEB Journal, 25(1), 358-369. https://doi.org/10.1096/fj.10-171579
- Scavo, L. M., Karas, M., Murray, M., & Leroith, D. (2004). Insulin-like growth factor-I stimulates both cell growth and lipogenesis during differentiation of human mesenchymal stem cells into adipocytes. Journal of Clinical Endocrinology & Metabolism, 89(7), 3543-3553. https://doi.org/10.1210/jc.2003-031842